225 related articles for article (PubMed ID: 32727735)
1. Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities.
Kelly MR; Kostyrko K; Han K; Mooney NA; Jeng EE; Spees K; Dinh PT; Abbott KL; Gwinn DM; Sweet-Cordero EA; Bassik MC; Jackson PK
Cancer Discov; 2020 Dec; 10(12):1950-1967. PubMed ID: 32727735
[TBL] [Abstract][Full Text] [Related]
2. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
[TBL] [Abstract][Full Text] [Related]
3. Identification of Radil as a Ras binding partner and putative activator.
Choi BH; Kou Z; Colon TM; Chen CH; Chen Y; Dai W
J Biol Chem; 2021; 296():100314. PubMed ID: 33482197
[TBL] [Abstract][Full Text] [Related]
4. A Proteomic Approach Identifies Isoform-Specific and Nucleotide-Dependent RAS Interactions.
Miller SP; Maio G; Zhang X; Badillo Soto FS; Zhu J; Ramirez SZ; Lin H
Mol Cell Proteomics; 2022 Aug; 21(8):100268. PubMed ID: 35839996
[TBL] [Abstract][Full Text] [Related]
5. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.
Baldelli E; Bellezza G; Haura EB; Crinó L; Cress WD; Deng J; Ludovini V; Sidoni A; Schabath MB; Puma F; Vannucci J; Siggillino A; Liotta LA; Petricoin EF; Pierobon M
Oncotarget; 2015 Oct; 6(32):32368-79. PubMed ID: 26468985
[TBL] [Abstract][Full Text] [Related]
6. Label-free quantitative proteomics and N-glycoproteomics analysis of KRAS-activated human bronchial epithelial cells.
Sudhir PR; Chen CH; Pavana Kumari M; Wang MJ; Tsou CC; Sung TY; Chen JY; Chen CH
Mol Cell Proteomics; 2012 Oct; 11(10):901-15. PubMed ID: 22761399
[TBL] [Abstract][Full Text] [Related]
7. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.
Sulahian R; Kwon JJ; Walsh KH; Pailler E; Bosse TL; Thaker M; Almanza D; Dempster JM; Pan J; Piccioni F; Dumont N; Gonzalez A; Rennhack J; Nabet B; Bachman JA; Goodale A; Lee Y; Bagul M; Liao R; Navarro A; Yuan TL; Ng RWS; Raghavan S; Gray NS; Tsherniak A; Vazquez F; Root DE; Firestone AJ; Settleman J; Hahn WC; Aguirre AJ
Cell Rep; 2019 Oct; 29(1):118-134.e8. PubMed ID: 31577942
[TBL] [Abstract][Full Text] [Related]
8. Synthetic lethal genetic screens in Ras mutant cancers.
Yu B; Luo J
Enzymes; 2013; 34 Pt. B():201-19. PubMed ID: 25034106
[TBL] [Abstract][Full Text] [Related]
9. Engineered variants of the Ras effector protein RASSF5 (NORE1A) promote anticancer activities in lung adenocarcinoma.
Singh A; Erijman A; Noronha A; Kumar H; Peleg Y; Yarden Y; Shifman JM
J Biol Chem; 2021 Dec; 297(6):101353. PubMed ID: 34717958
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors.
Symonds JM; Ohm AM; Carter CJ; Heasley LE; Boyle TA; Franklin WA; Reyland ME
Cancer Res; 2011 Mar; 71(6):2087-97. PubMed ID: 21335545
[TBL] [Abstract][Full Text] [Related]
11. Targeted data-independent acquisition for mass spectrometric detection of RAS mutations in formalin-fixed, paraffin-embedded tumor biopsies.
Kim YJ; Chambers AG; Cecchi F; Hembrough T
J Proteomics; 2018 Oct; 189():91-96. PubMed ID: 29684684
[TBL] [Abstract][Full Text] [Related]
12. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
[TBL] [Abstract][Full Text] [Related]
14. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Proteomics Combined with Affinity MS Revealed the Molecular Mechanism of Ginsenoside Antitumor Effects.
Wang Z; Kim U; Jiao Y; Li C; Guo Y; Ma X; Jiang M; Jiang Z; Hou Y; Bai G
J Proteome Res; 2019 May; 18(5):2100-2108. PubMed ID: 30860844
[TBL] [Abstract][Full Text] [Related]
16. Quantitative proteomic approach to understand metabolic adaptation in non-small cell lung cancer.
Martín-Bernabé A; Cortés R; Lehmann SG; Seve M; Cascante M; Bourgoin-Voillard S
J Proteome Res; 2014 Nov; 13(11):4695-704. PubMed ID: 25029028
[TBL] [Abstract][Full Text] [Related]
17. Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib.
Nolan A; Raso C; Kolch W; Kriegsheim AV; Wynne K; Matallanas D
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627169
[TBL] [Abstract][Full Text] [Related]
18. KRAS mutations in lung cancer.
Karachaliou N; Mayo C; Costa C; Magrí I; Gimenez-Capitan A; Molina-Vila MA; Rosell R
Clin Lung Cancer; 2013 May; 14(3):205-14. PubMed ID: 23122493
[TBL] [Abstract][Full Text] [Related]
19. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
[TBL] [Abstract][Full Text] [Related]
20. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.
Amann JM; Lee JW; Roder H; Brahmer J; Gonzalez A; Schiller JH; Carbone DP
J Thorac Oncol; 2010 Feb; 5(2):169-78. PubMed ID: 20035238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
